3D bioprinting is among the most innovative technologies in the world today. It involves creating human tissues using biomaterials as 'inks' and printing layer-by-layer to create living structures. These formed structures mimic the behavior of their natural living counterparts and are used for pharmaceutical development, drug validation, bioengineering, and regenerative medicine. What is 3D bioprinting? It is a cutting-edge process that combines 3D printing techniques with biological systems to fabricate complex tissue constructs. The rising demand for personalized medicine and advanced drug discovery has positioned 3D bioprinting companies as key innovators in the biotech industry.
Here are some of the world’s most innovative 3D bioprinting companies and 3D printing startups in 2025:
CELLINK (Part of BICO Group AB)
Located in the US, CELLINK, now part of the BICO Group, develops some of the best 3D bioprinters and technologies on the market. This technology enables breakthroughs in 3D printing bioprinting for cell culturing and drug development. It was the first company to release the universal bioink in 2016 and has played a crucial role in turning 3D printer bioprinting into a multi-billion-dollar industry. Under BICO, it continues to expand its applications in healthcare and tissue engineering, including partnerships with academic and industrial leaders to accelerate regenerative medicine. Additionally, CELLINK has contributed to the advancement of personalized medicine by offering tools for creating patient-specific tissues. In 2025, CELLINK is also focusing on automation in 3D bioprinting workflows to improve scalability for clinical applications.
Located in the US, ALLEVI, acquired by 3D Systems in 2021, develops 3D bioprinters and bioinks to test novel drugs, cure diseases, and eliminate the organ waitlist. It uses a special bioink combined with biomaterials to build living 3D tissue and human organs for its clients. Integration with 3D Systems has enhanced its bioprinting solutions for advanced applications, such as high-throughput screening and personalized medicine. ALLEVI’s commitment to accessibility has also resulted in user-friendly solutions for academic and research laboratories. Its recent innovations include expanding the use of its 3D bioprinters for high-precision tissue modeling in regenerative medicine.
Located in the US, Organovo Holdings develops therapeutics and drug profiling capabilities based on 3D bioprinting tissues that mimic the critical aspects of diseases and their biology. It has shifted focus to therapeutic applications, particularly liver tissues, and continues to innovate using its proprietary 3D printing platform to generate human tissue for research and drug discovery. Recent efforts include exploring partnerships for bioprinted tissue implants in clinical applications and advancing preclinical testing models for pharmaceutical companies. Organovo is actively collaborating with healthcare providers to refine the therapeutic use of bioprinted liver tissue in transplantation research.
Based in Israel, CollPlant focuses on regenerative medicine, leveraging its plant-based collagen bioink for 3D bioprinting. Its collaboration with United Therapeutics aims to develop bioprinted lungs for transplantation. CollPlant’s bioinks are highly regarded for their biocompatibility and versatility in creating tissues and organs. In addition to lungs, CollPlant is working on dermal fillers and breast implants to further expand its footprint in the medical field. The company has also received recognition for its scalable manufacturing processes and is now exploring new markets such as orthopedics and wound care.
Located in the US, Prellis Biologics specializes in printing vascularized tissue models for drug discovery and regenerative medicine. Its proprietary holographic printing technology enables the creation of complex, functional tissues at high resolution, advancing the development of human organ models. Prellis has also made significant progress in creating miniaturized lymph node structures for immunotherapy research, allowing researchers to better study immune responses in vitro. In 2025, Prellis is working on scalable solutions for printing microvasculature to improve the integration of bioprinted tissues into live systems.
BRINTER
Located in Finland, BRINTER prints tissue models layer-by-layer using a cell-laden hydrogel solution loaded onto their 3D printer. These constructs are later evaluated to ensure structural integrity. It also develops personalized medicine for treating cancer by 3D printing patient-specific tumors and then testing potential drugs on them. Brinter’s modular 3D printing platforms have gained attention for their adaptability to a wide range of research needs. The company has also ventured into pharmaceutical applications by printing controlled-release drug delivery systems. Its advancements in modular design make it one of the most versatile 3D bioprinting companies in the field.
Located in the US, TeVido Biodevices uses 3D printers for reconstructive and cosmetic surgeries designed for breast cancer survivors. It applies patients' melanocytes during 3D printing to lower the chance of rejection. TeVido Biodevices offers treatments such as nipple reconstruction and cell therapy for patients suffering from vitiligo. The company is also exploring applications in wound healing and skin regeneration, positioning itself as a leader in personalized medicine for dermatology. In 2025, TeVido has expanded its offerings to include bioprinted scaffolds for advanced dermatological treatments.
Located in Germany, Cellbricks uses novel stereolithography techniques for 3D bioprinting. Cellbricks exemplifies this technology by utilizing photochemical processes to create complex 3D structures using multiple bioinks simultaneously. Cellbricks specializes in creating customized organ models, 3D cell cultures, and scaffolds. Their recent advancements include producing high-resolution, functional liver models for pharmaceutical testing. The company has also partnered with academic institutions to expand its research capabilities. In 2025, Cellbricks is developing bioprinted kidney structures to address the growing need for organ transplantation solutions.
Located in Canada, Aspect Biosystems utilizes its proprietary 3D bioprinting platform to assist researchers in developing therapeutics and regenerative medicine. It has been working in collaboration with Frampton Lab at Dalhousie University to create synthetic tissue and is in a partnership with Johnson & Johnson to 3D print knee meniscus tissue. The company’s platform is also being applied in the development of cell therapies for chronic diseases. Aspect Biosystems has made strides in creating tissue constructs that integrate seamlessly into preclinical models. The company’s recent focus includes bioprinted cardiac patches for heart disease research.
Located in Japan, Cyfuse enables faster tissue generation by using a tissue fabrication process that doesn't require scaffolds such as polymers or collagen. It uses robotic systems for tissue fabrication that can assemble spheroids into complex 3D shapes. Its scaffold-free approach has accelerated advancements in regenerative medicine, with a focus on commercializing tissue patches for clinical use. Cyfuse’s technology is also being adapted for applications in regenerative orthopedics and neurology. In 2025, Cyfuse has unveiled a pilot program for bioprinted nerve repair grafts.
Conclusion
The 3D bioprinting industry is at the forefront of revolutionizing healthcare, regenerative medicine, and pharmaceutical development. Companies like CELLINK, ALLEVI, and CollPlant are pioneering innovations that bring us closer to addressing critical medical challenges, including organ shortages and personalized therapies. By leveraging advanced technologies like stereolithography, holographic printing, and scaffold-free tissue fabrication, these 3D printing startups are redefining the possibilities in biotechnology. As the industry grows, platforms like Scispot ensure that these 3D bioprinting companies can streamline operations, drive innovation, and scale effectively. The future of 3D bioprinting is undoubtedly bright, with limitless potential to transform medicine and improve lives globally.
